Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 12, 2010, Pages 1784-1793

  Toklu, Hale Z ^a   Şehirli, Özer ^a   Erşahin, Mehmet ^b   Süleymanoǧlu, Selami ^a   Yiǧiner, Ömer ^a   Emekli Alturfan, Ebru ^c   Yarat, Ayşen ^c   Yeǧen, Berrak Ç ^d   Şener, Göksel ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Hypertension; Na+ K+ ATPase; Oxidative stress; Resveratrol

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIOXIDANT; CATALASE; GLUTATHIONE; MYELOPEROXIDASE; RESVERATROL; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL REACTIVITY; BRAIN INJURY; BRAIN TISSUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; HEART FUNCTION; HEART VENTRICLE FUNCTION; HYPERTENSION; KIDNEY INJURY; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PARAMETER; RAT; RENOVASCULAR HYPERTENSION; VASCULAR RING;

ANIMALS; ANTIOXIDANTS; BRAIN; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CATALASE; GLUTATHIONE; HEART; KIDNEY; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PEROXIDASE; RATS; RATS, WISTAR; STILBENES; SUPEROXIDE DISMUTASE;

EID: 78149382534     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01197.x     Document Type: Article

References (66)

1. Navar LG et al. Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 1998; 13: 170-176.
2. Oliveira-Sales EB et al. Oxidative stress contributes to renovascular hypertension. Am J Hypertens 2008; 21: 98-104.
3. Plantinga LC et al. Early, intermediate, and long-term risk factors for mortality in incident dialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Am J Kidney Dis 2007; 49: 831-840.
4. Keys A et al. The diet and 15-year death rate in the seven countries study. Am J Epidemiol 1986; 124: 903-915.
5. Das DK et al. Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp Clin Res 1999; 25: 115-120.
6. Wang Z et al. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002; 9: 77-79.
7. Wang Z et al. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med 2005; 16: 533-540.
8. De La Lastra CA et al. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res 2005; 49: 405-430.
9. Hattori R et al. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 2002; 282: H1988-H1995.
10. Labinskyy N et al. Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr Med Chem 2006; 13: 989-996.
11. Zern TL et al. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr 2005; 135: 1911-1917.
12. Sebai H et al. Protective effect of resveratrol against lipopolysaccharide-induced oxidative stress in rat brain. Brain Inj 2009; 23: 1089-1094.
13. Wang J et al. Resveratrol protects against cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother Radiopharm 2009; 24: 675-680.
14. Chander V, Chopra K. Protective effect of resveratrol, a polyphenolic phytoalexin on glycerol-induced acute renal failure in rat kidney. Ren Fail 2006; 28: 161-169.
15. Navar LG et al. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002; 39: 316-322.
16. Helle F et al. Angiotensin II-induced calcium signaling in the afferent arteriole from rats with two-kidney, one-clip hypertension. Am J Physiol Renal Physiol 2006; 291: F140-F147.
17. Tatlidede E et al. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 2009; 43: 195-205.
18. Schiller NB et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
19. Mylroie AA et al. Erythrocyte superoxide dismutase activity and other parameters of copper status in rats ingesting lead acetate. Toxicol Appl Pharmacol 1986; 82: 512-520.
20. Aebi H. Catalase in vitro. Methods Enzymol, 1984; 105: 121-126.
21. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-310.
22. Beutler E. Glutathione in red blood cell metabolism. In: Red Cell Metabolism: A Manual of Biochemical Methods. New York: Grune Stratton, 1975: 112-114.
23. Hillegass LM et al. Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 1990; 24: 285-295.
24. Kim YK et al. Effect of ethanol on organic ion transport in rabbit kidney. Toxicol Appl Pharmacol 1986; 86: 411-420.
25. Reading HW, Isbir T. The role of cation-activated ATPases in transmitter release from the rat iris. Q J Exp Physiol Cogn Med Sci 1980; 65: 105-116.
26. Fiske CH, SubbaRow Y. The colorimetric determination of phosphorus. J Biol Chem 1925; 66: 375-400.
27. Lowry OH et al. Protein measurements with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
28. Kurz S et al. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation 1999; 99: 3181-3187.
29. Shinozaki K et al. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 2004; 43: 255-262.
30. Costa CA et al. Antioxidant treatment with tempol and apocynin prevents endothelial dysfunction and development of renovascular hypertension. Am J Hypertens 2009; 22: 1242-1249.
31. Chen X et al. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001; 38: 606-611.
32. Kawada N et al. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol 2002; 13: 2860-2868.
33. Rajagopalan S et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
34. Sarr M et al. Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase. Cardiovasc Res 2006; 71: 794-802.
35. Ungvari Z et al. Resveratrol increases vascular oxidative stress resistance. Am J Physiol Heart Circ Physiol 2007; 292: H2417-H2424.
36. Shigematsu S et al. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 2003; 34: 810-817.
37. Willcox BJ et al. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol 2008; 101: 75D-86D.
38. De Nigris F et al. Oxidation-sensitive transcription factors and molecular mechanisms in the arterial wall. Antioxid Redox Signal 2001; 3: 1119-1130.
39. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27: 101-110.
40. Higashi Y et al. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1954-1962.
41. Novakovic A et al. The mechanism of endothelium-independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery. J Pharmacol Sci 2006; 101: 85-90.
42. Wallerath T et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002; 106: 1652-1658.
43. Mizutani K et al. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 2000; 46: 78-83.
44. Rush JW et al. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp Biol Med (Maywood) 2007; 232: 814-822.
45. Toklu H et al. Resveratrol supplementation protects against chronic nicotine-induced oxidative damage and organ dysfunction in the rat urogenital system. Marmara Pharm J 2010; 14: 29-40.
46. Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 2006; 48: 326-341.
47. Thandapilly SJ et al. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am J Hypertens 2010; 23: 192-196.
48. Chow SE et al. Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol 2007; 102: 1520-1527.
49. Ray PS et al. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 1999; 27: 160-169.
50. Wallerath T et al. Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects. J Am Coll Cardiol 2003; 41: 471-478.
51. El Midaoui A et al. Comparative effects of N-acetyl-L-cysteine and ramipril on arterial hypertension, insulin resistance, and oxidative stress in chronically glucose-fed rats. Can J Physiol Pharmacol 2008; 86: 752-760.
52. Majithiya JB et al. Effect of pioglitazone on L-NAME induced hypertension in diabetic rats. Vascul Pharmacol 2005; 43: 260-266.
53. Rodrigo R et al. Relationship between (Na + K)-ATPase activity, lipid peroxidation and fatty acid profile in erythrocytes of hypertensive and normotensive subjects. Mol Cell Biochem 2007; 303: 73-81.
54. Russo C et al. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens 1998; 16: 1267-1271.
55. Laursen JB et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-593.
56. Schnackenberg CG et al. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 1998; 32: 59-64.
57. Swei A et al. A mechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation 1999; 6: 179-187.
58. Cohuet G et al. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther 2006; 111: 81-98.
59. Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 2002; 282: R335-R342.
60. Chade AR et al. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 2004; 15: 958-966.
61. Jain SK, Lim G. Lipoic acid decreases lipid peroxidation and protein glycosylation and increases (Na(+) + K(+))- and Ca(++)-ATPase activities in high glucose-treated human erythrocytes. Free Radic Biol Med 2000; 29: 1122-1128.
62. Sener G et al. Resveratrol improves ischemia/reperfusion-induced oxidative renal injury in rats. Arch Med Res 2006; 37: 822-829.
63. Solmaz A et al. Protective and therapeutic effects of resveratrol on acetic acid-induced gastric ulcer. Free Radic Res 2009; 43: 594-603.
64. Kettle AJ et al. Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Redox Rep 1997; 3: 257-258.
65. Sener G et al. Protective effects of resveratrol against acetaminophen-induced toxicity in mice. Hepatol Res 2006; 35: 62-68.
66. Sener G et al. Resveratrol alleviates bleomycin-induced lung injury in rats. Pulm Pharmacol Ther 2007; 20: 642-649.